Journal
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Volume 95, Issue -, Pages 279-293Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejpb.2015.02.019
Keywords
Nanoparticles; Nanotechnology; Ocular; Topical administration; Drug delivery; Gene delivery
Categories
Funding
- Carlos III Health Institute, Spain (Miguel Servet Program) [CP12/03150]
- Ministry of Economy and Competitivity (SURFeye) [RTC-2014-2375-1]
- Xunta de Galicia
Ask authors/readers for more resources
The topical route is the most frequent and preferred way to deliver drugs to the eye. Unfortunately, the very low ocular drug bioavailability (less than 5%) associated with this modality of administration, makes the efficient treatment of several ocular diseases a significant challenge. In the last decades, it has been shown that specific nanocarriers can interact with the ocular mucosa, thereby increasing the retention time of the associated drug onto the eye, as well as its permeability across the corneal and conjunctival epithelium. In this review, we comparatively analyze the mechanism of action and specific potential of the most studied nano-drug delivery carriers. In addition, we present the success achieved until now using a number of nanotherapies for the treatment of the most prevalent ocular pathologies, such as infections, inflammation, dry eye, glaucoma, and retinopathies. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available